Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Ruxolitinib and Surgical Interventions

July 7th 2020

Ruxolitinib for Primary Myelofibrosis

July 7th 2020

Treating Intermediate/High-Risk Primary Myelofibrosis

July 7th 2020

Management of Low-Risk Primary Myelofibrosis

July 7th 2020

Primary Myelofibrosis: Risk Stratification

July 7th 2020

Polycythemia Vera: PROUD-PV Trial

July 7th 2020

Utilization of Ruxolitinib for Polycythemia Vera

July 7th 2020

Polycythemia Vera: Ruxolitinib Trial Data

July 7th 2020

Polycythemia Vera: Switching Therapy

July 7th 2020

Treatment Options for High-Risk Polycythemia Vera

July 7th 2020

Management of Low-Risk Polycythemia Vera

July 7th 2020

Polycythemia Vera: Monitoring Patients

July 7th 2020

Polycythemia Vera: Risk Assessment

July 7th 2020

Polycythemia Vera: Prognostic Markers

July 7th 2020

Polycythemia Vera: Bone Marrow Biopsies

July 7th 2020

Polycythemia Vera: Diagnostic Work-up

July 7th 2020

Characterization of Myeloproliferative Neoplasms

July 7th 2020

Dr. Yee on the Utility of Isatuximab in Combination Therapy for Relapsed/Refractory Myeloma

July 6th 2020

Andrew Yee, MD, discusses the utility of isatuximab-irfc in relapsed/refractory multiple myeloma.

FDA Lifts Partial Clinical Hold on Camidanlumab Tesirine R/R Hodgkin Lymphoma Trial

July 6th 2020

The FDA has lifted a partial clinical hold that was placed on the phase 2 clinical trial of camidanlumab tesirine in patients with relapsed/refractory Hodgkin lymphoma.

Venetoclax/Azacitidine Slated as New Standard in Older Patients With AML Ineligible for Intensive Therapy

July 6th 2020

Courtney D. DiNardo, MD, MSCE, discusses the results of the study evaluating the combination of azacitidine plus venetoclax in elderly patients with AML.